Form 4 for ORGO Organogenesis Holdings Inc.
Accepted 2023-02-24 00:00:00 ET · period of report 2023-02-22 · accession 0001062993-23-004890 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-24 | 2023-02-22 | ORGO | Grow Brian | Chief Commercial Off | A - Grant | $0.00 | +291.0K | 374.6K | +348% | $0 |
| D | 2023-02-24 | 2023-02-22 | ORGO | Grow Brian | Chief Commercial Off | A - Grant | $0.00 | +345.5K | 345.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-02-22 | A | A | 291,009 | $0.00 | 374,608 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-02-22 | A | A | 345,470 | $0.00 | 345,470 | D | $2.51 · — to 2033-02-22 | 345,470 Class A Common Stock | (F2) The option becomes exercisable in equal annual installments over four years beginning February 15, 2023. |